Cyclophosphamide and Doxorubicin (CA x 4 Cycles) Versus Paclitaxel (4 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0--3 Positive Axillary Lymph Nodes: A Phase III Randomized Study
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, and
paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or
die. Combining more than one drug may kill more tumor cells. It is not yet known whether
giving cyclophosphamide together with doxorubicin is more effective than giving paclitaxel
alone in treating breast cancer.
PURPOSE: This randomized phase III trial is studying cyclophosphamide and doxorubicin to see
how well they work compared to paclitaxel in treating women with invasive breast cancer.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.